TCGA-78-7539-01A-11R-2066-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.360
- IL6_JAK_STAT3_SIGNALING+0.220
- BILE_ACID_METABOLISM+0.190
- IL2_STAT5_SIGNALING+0.190
- OXIDATIVE_PHOSPHORYLATION+0.170
- APOPTOSIS+0.140
- PROTEIN_SECRETION+0.140
- ESTROGEN_RESPONSE_EARLY+0.130
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ANGIOGENESIS-0.400
- MYC_TARGETS_V1-0.350
- MYC_TARGETS_V2-0.350
- MTORC1_SIGNALING-0.330
- HYPOXIA-0.300
- MITOTIC_SPINDLE-0.300
- APICAL_SURFACE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320087 | — | — | 0.832 |
| 2 | 82988 | EPN | Supratentorial EPN | 0.826 |
| 3 | SRR2778078 | — | — | 0.823 |
| 4 | SRR8518296 | — | A | 0.820 |
| 5 | MDT-AP-1175 | Med | Medulloblastoma | 0.817 |
| 6 | 0bdec778-829d-4cba-8d0f-dcaa0d8803b1 | — | — | 0.811 |
| 7 | EPT0505 | EPN | EPN Tumor | 0.810 |
| 8 | SRR13780265 | — | cohortMD2 | 0.806 |
| 9 | TCGA-OR-A5LN-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.806 |
| 10 | X44dc4429.1bfa.4845.b2ed.028feafe7d4a | — | cohortA1 | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |